Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | ARG1 | P05089 | 4/20 | 0.42 |
| ▸ | DPP4 | P27487 | 3/20 | 0.38 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.38 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | ARG2 | P78540 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL1820143 | 1.00 | MEN1 (0.52) | MEN1BLMKMT2ASLC1A2ARG1 | |
| Proline SCHEMBL4398037 | 0.91 | MEN1 (0.44) | MEN1BLMKMT2ASLC1A2ARG1 | |
| Proline SCHEMBL28467818 | 0.91 | MEN1 (0.44) | MEN1BLMKMT2ASLC1A2ARG1 | |
| Proline SCHEMBL1196246 | 0.91 | MEN1 (0.44) | MEN1BLMKMT2ASLC1A2ARG1 | |
| Proline SCHEMBL10979350 | 0.88 | MEN1 (0.41) | MEN1BLMKMT2ASLC1A2ARG1 | |
| Proline SCHEMBL10828992 | 0.86 | MEN1 (0.40) | MEN1BLMKMT2ASLC1A2ARG1 | |
| SCHEMBL351910 | 0.85 | MEN1 (0.63) | MEN1BLMKMT2ASLC1A2ARG1 | |
| SCHEMBL12909421 | 0.85 | MEN1 (0.63) | MEN1BLMKMT2ASLC1A2ARG1 | |
| SCHEMBL2964298 | 0.85 | MEN1 (0.63) | MEN1BLMKMT2ASLC1A2ARG1 | |
| SCHEMBL17943259 | 0.85 | MEN1 (0.63) | MEN1BLMKMT2ASLC1A2ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743102-A1 | COLLAGEN PEPTIDE COMPOSITION AND USE THEREOF IN AMELIORATING NEUROLOGICAL CONDITIONS AND FIBROSIS | Rousselot BV (BE) | 2026-05-20 | — | — | EP | claimed |
| US-20250152494-A1 | COSMETIC COMPOSITION CONTAINING RETINOID, EXTRACT OF CENTELLA ASIATICA AND A DIPEPTIDE | THE BOOTS COMPANY PLC (GB) | 2025-05-15 | — | — | US | claimed |
| CN-115317589-B | Prolyl hydroxylase inhibitors and uses thereof | 中国海洋大学 | 2024-12-13 | — | — | CN | claimed |
| CN-116794202-A | Screening and application of metabolic markers of rifampicin drug-resistant tuberculosis | 首都医科大学附属北京胸科医院 | 2023-09-22 | — | — | CN | claimed |
| CN-115317589-A | Prolyl hydroxylase inhibitors and uses thereof | 中国海洋大学 | 2022-11-11 | — | — | CN | claimed |
| EP-2617407-A2 | Mild face cleansing agent having skin care properties | Henkel AG&Co. KGAA (DE) | 2013-07-24 | — | — | EP | claimed |
| US-20120238030-A1 | Methods and Systems for Multiplex Analysis of Biomolecules by Liquir Chromatography-Mass Spectrometry | LABORATORY CORPORATION OF AMERICA HOLDINGS (US) | 2012-09-20 | — | — | US | claimed |
| US-20070116819-A1 | High-Potency Sweetener Composition with Fatty Acid and Compositions Sweetened Therewith | THE COCA-COLA COMPANY (US) | 2007-05-24 | — | — | US | claimed |
| WO-2004110470-A2 | USE OF COLLAGEN PEPTIDES TO INHIBIT INFECTION | THE UNIVERSITY OF BRISTOL (GB) | 2004-12-23 | — | — | WO | claimed |
| EP-0036713-A2 | Angiotensin converting enzyme inhibitors | UNIVERSITY OF MIAMI (US) | 1981-09-30 | — | — | EP | claimed |
| EP-4743102-A1 | COLLAGEN PEPTIDE COMPOSITION AND USE THEREOF IN AMELIORATING NEUROLOGICAL CONDITIONS AND FIBROSIS | Rousselot BV (BE) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026087731-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMINO ACID COMPOSITION IN PURIFIED HYALURONIC ACID | INTIBIO BV (BE) | 2026-04-30 | — | — | WO | disclosed |
| US-20260115150-A1 | FORMULATIONS COMPRISING INOSITOL, SILICATES, AND OPTIONALLY AMINO ACIDS WITH IMPROVED SOLUBILITY AND METHODS OF MAKING THE SAME | NUTRITION21 LLC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | disclosed |
| US-12569532-B2 | Brain function regulating agent, and food or beverage product containing same | NITTA GELATIN INC. (JP) | 2026-03-10 | — | — | US | disclosed |
| WO-1993011781-A1 | SYNTHETIC COMPOUNDS AND COMPOSITIONS WITH ENHANCED CELL BINDING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1993-06-24 | — | — | WO | disclosed |
| EP-0487617-A4 | SYNTHETIC PEPTIDES THAT ENHANCE CELL BINDING | — | 1992-07-08 | — | — | EP | disclosed |
| EP-0487617-A1 | SYNTHETIC PEPTIDES THAT ENHANCE CELL BINDING. | UNIV CALIFORNIA (US) | 1992-06-03 | — | — | EP | disclosed |
| WO-1991002537-A1 | SYNTHETIC PEPTIDES THAT ENHANCE CELL BINDING | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1991-03-07 | — | — | WO | disclosed |
| EP-0355131-A1 | ACYL DEOXYRIBONUCLEOSIDE DERIVATIVES AND USES THEREOF | PRO-NEURON, INC. (US) | 1990-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12569532-B2 | Brain function regulating agent, and food or beverage product containing same | PYGB, CASP10, BDNF | MEN1 1936/4885BLM 4584/4885KMT2A 3352/4885 |
| US-20250152494-A1 | COSMETIC COMPOSITION CONTAINING RETINOID, EXTRACT OF CENTELLA ASIATICA AND A DIPEPTIDE | RARA, RARG, RARB | MEN1 3331/4885BLM 2345/4885KMT2A 2180/4885 |
| US-20260115150-A1 | FORMULATIONS COMPRISING INOSITOL, SILICATES, AND OPTIONALLY AMINO ACIDS WITH IMPROVED SOLUBILITY AND METHODS OF MAKING THE SAME | CUTA, NOS1, NOS2 | MEN1 883/4885BLM 3655/4885KMT2A 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.